AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

Emraclidine is a potential novel M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The ...

AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia experiencing acute exacerbation of ...

Emraclidine is also in phase 1 for Alzheimer's disease psychosis, which also has FDA Fast Track designation. However, this is a much smaller market than the schizophrenia indication would have been.

AbbVie’s treatment, emraclidine, which it got the drug through its $9 billion acquisition of Cerevel Therapeutics, failed to significantly help patients. Skip to Main Content.

Investigators evaluated emraclidine in patients with schizophrenia who are experiencing an acute exacerbation in two placebo-controlled Phase II trials, which included EMPOWER-1 and EMPOWER-2. The ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of ...

AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...